Brian R. Lawson
Scripps Research Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brian R. Lawson.
Journal of Clinical Investigation | 2002
Wolfgang Dummer; Andreas G. Niethammer; Roberto Baccala; Brian R. Lawson; Norbert Wagner; Ralph A. Reisfeld; Argyrios N. Theofilopoulos
Development of tumor immunotherapies focuses on inducing autoimmune responses against tumor-associated self-antigens primarily encoded by normal, unmutated genes. We hypothesized that such responses could be elicited by T cell homeostatic proliferation in the periphery, involving expansion of T cells recognizing self-MHC/peptide ligands. Herein, we demonstrate that sublethally irradiated lymphopenic mice transfused with autologous or syngeneic T cells showed tumor growth inhibition when challenged with melanoma or colon carcinoma cells. Importantly, the antitumor response depended on homeostatic expansion of a polyclonal T cell population within lymph nodes. This response was effective even for established tumors, was characterized by CD8(+) T cell-mediated tumor-specific cytotoxicity and IFN-gamma production, and was associated with long-term memory. The results indicate that concomitant induction of the physiologic processes of homeostatic T cell proliferation and tumor antigen presentation in lymph nodes triggers a beneficial antitumor autoimmune response.
Nature | 2013
Vishal Deshmukh; Virginie Tardif; Costas A. Lyssiotis; Chelsea C. Green; Bilal E. Kerman; Hyung Joon Kim; Krishnan Padmanabhan; Jonathan G. Swoboda; Insha Ahmad; Toru Kondo; Fred H. Gage; Argyrios N. Theofilopoulos; Brian R. Lawson; Peter G. Schultz; Luke L. Lairson
Progressive phases of multiple sclerosis are associated with inhibited differentiation of the progenitor cell population that generates the mature oligodendrocytes required for remyelination and disease remission. To identify selective inducers of oligodendrocyte differentiation, we performed an image-based screen for myelin basic protein (MBP) expression using primary rat optic-nerve-derived progenitor cells. Here we show that among the most effective compounds identifed was benztropine, which significantly decreases clinical severity in the experimental autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered alone or in combination with approved immunosuppressive treatments for multiple sclerosis. Evidence from a cuprizone-induced model of demyelination, in vitro and in vivo T-cell assays and EAE adoptive transfer experiments indicated that the observed efficacy of this drug results directly from an enhancement of remyelination rather than immune suppression. Pharmacological studies indicate that benztropine functions by a mechanism that involves direct antagonism of M1 and/or M3 muscarinic receptors. These studies should facilitate the development of effective new therapies for the treatment of multiple sclerosis that complement established immunosuppressive approaches.
Arthritis Research & Therapy | 2001
Argyrios N. Theofilopoulos; Stefanos Koundouris; Dwight H. Kono; Brian R. Lawson
The classification of T helper cells into type 1 (Th1) and type 2 (Th2) led to the hypothesis that Th1 cells and their cytokines (interleukin [IL]-2, interferon [IFN]-γ) are involved in cell-mediated autoimmune diseases, and that Th2 cells and their cytokines (IL-4, IL-5, IL-10, IL-13) are involved in autoantibody(humoral)-mediated autoimmune diseases. However, this paradigm has been refuted by recent studies in several induced and spontaneous mouse models of systemic lupus erythematosus, which showed that IFN-γ is a major effector molecule in this disease. These and additional findings, reviewed here, suggest that these two cross-talking classes of cytokines can exert autoimmune disease-promoting or disease-inhibiting effects without predictability or strict adherence to the Th1-versus-Th2 dualism.
Annals of the Rheumatic Diseases | 1999
Argyrios N. Theofilopoulos; Brian R. Lawson
Investigations into the structure, expression and functional status of cytokines, as well as on the possible utility of their agonists and antagonists as therapeutic agents in lupus, have received prominent attention. In fact, mouse strains predisposed to lupus (NZBxW, BXSB, MRL- lpr ) have long constituted the primary resource to investigate the role of cytokines in autoimmunity. An additional impetus for such investigations in recent years has been provided by the discovery that T cells may be polarised during an ongoing immune response into the so called TH1 and TH2 subsets, which display distinct cytokine profiles and effector functions. Thus, following antigen recognition, cytokines present at the site of priming together with other factors, such as type of antigen presenting cell, amount of antigen, co-stimulatory molecules, affinity and duration of exposure direct the induction of either TH1 cells, which secrete IL2, IFNγ and TNFβ, or TH2 cells, which secrete IL4, IL5, IL6, IL10 and IL13.1 Another cytokine, IL12, produced by activated macrophages and dendritic cells, is a strong inducer of TH1 cells in which the β-subunit of its receptor is retained but lost on TH2 cells. The former cells then provide protection from intracellular pathogens, activate phagocytes, induce IgG2a antibodies, and promote DTH responses, whereas the latter cells provide protection from extracellular pathogens, activate eosinophils, induce IgE mediated allergic reactions, and generally promote humoral responses in which IgG1 predominates. The molecular events associated with this polarisation have not been fully eludicated, but certain protooncogenes, kinases and transcription factors seem to play a part.2-6 Based on this T cell division, it has been hypothesised that organ specific autoimmune diseases such as IDDM should be mediated by TH1 cells, whereas humorally mediated autoimmune diseases such as lupus …
Immunity | 2008
M. Katarina Haraldsson; Christine A. Louis-Dit-Sully; Brian R. Lawson; Gabriel Sternik; Marie-Laure Santiago-Raber; Nicholas R. J. Gascoigne; Argyrios N. Theofilopoulos; Dwight H. Kono
Here, we show that a lupus-suppressing locus is caused by a nonsense mutation of the filamentous actin-inhibiting Coronin-1A gene. This mutation was associated with developmental and functional alterations in T cells including reduced migration, survival, activation, and Ca2+ flux. T-dependent humoral responses were impaired, but no intrinsic B cell defects were detected. By transfer of T cells, it was shown that suppression of autoimmunity could be accounted for by the presence of the Coro1a(Lmb3) mutation in T cells. Our results demonstrate that Coronin-1A is required for the development of systemic lupus and identify actin-cytoskeleton regulatory proteins as potential targets for modulating autoimmune diseases.
Proceedings of the National Academy of Sciences of the United States of America | 2008
Ben A. Croker; Brian R. Lawson; Michael Berger; Céline Eidenschenk; Amanda L. Blasius; Eva Marie Y Moresco; Sosathya Sovath; Louise H. Cengia; Leonard D. Shultz; Argyrios N. Theofilopoulos; Sven Pettersson; Bruce Beutler
A recessive phenotype called spin (spontaneous inflammation) was induced by N-ethyl-N-nitrosourea (ENU) mutagenesis in C57BL/6J mice. Homozygotes display chronic inflammatory lesions affecting the feet, salivary glands and lungs, and antichromatin antibodies. They are immunocompetent and show enhanced resistance to infection by Listeria monocytogenes. TLR-induced TNF and IL-1 production are normal in macrophages derived from spin mice. The autoinflammatory phenotype of spin mice is fully suppressed by compound homozygosity for Myd88poc, Irak4otiose, and Il1r1-null mutations, but not Ticam1Lps2, Stat1m1Btlr, or Tnf-null mutations. Both autoimmune and autoinflammatory phenotypes are suppressed when spin homozygotes are derived into a germ-free environment. The spin phenotype was ascribed to a viable hypomorphic allele of Ptpn6, which encodes the tyrosine phosphatase SHP1, mutated in mice with the classical motheaten alleles me and me-v. Inflammation and autoimmunity caused by SHP1 deficiency are thus conditional. The SHP1-deficient phenotype is driven by microbes, which activate TLR signaling pathways to elicit IL-1 production. IL-1 signaling via MyD88 elicits inflammatory disease.
Journal of Immunology | 2001
Marie-Laure Santiago-Raber; Brian R. Lawson; Wolfgang Dummer; Marlene Barnhouse; Stefanos Koundouris; Curtis B. Wilson; Dwight H. Kono; Argyrios N. Theofilopoulos
The cyclin kinase inhibitor protein p21 affects multiple processes relevant to the immune system, including cell cycle progression, replicative senescence, hemopoietic stem cell quiescence, and apoptosis. Therefore, malfunction of this protein may be a contributor to the pathogenesis of systemic autoimmunity. Here, we report that mixed background p21-deficient 129/Sv × C57BL/6 mice showed increased in vitro and in vivo T cell cycling and activation, moderate hypergammaglobulinemia and, at low penetrance, anti-chromatin autoantibodies. Homeostatic anti-self MHC/peptide ligand-induced proliferation of p21-deficient T cells was also enhanced. However, lymphoid organ enlargement was very mild, presumably due to increased apoptosis of the rapidly dividing cells. Moreover, the older p21-deficient mice had kidney pathology representing a similar, but slightly more advanced, state than that seen in the control mice. The timing and severity of the above serologic, cellular, and histologic manifestations in p21-deficient mice were unaffected by gender. Thus, p21 deficiency significantly enhances T cell activation and homeostatic proliferation, and can induce mild autoimmune manifestations at a low incidence without gender bias, but does not in itself generate the full spectrum of lupus-like disease.
Nature Reviews Rheumatology | 2009
Roberto Baccala; Rosana Gonzalez-Quintial; Brian R. Lawson; Michael E. Stern; Dwight H. Kono; Bruce Beutler; Argyrios N. Theofilopoulos
The discovery of molecular sensors that enable eukaryotes to recognize microbial pathogens and their products has been a key advance in our understanding of innate immunity. A tripartite sensing apparatus has developed to detect danger signals from infectious agents and damaged tissues, resulting in an immediate but short-lived defense response. This apparatus includes Toll-like receptors, retinoid acid-inducible gene-I-like receptors and other cytosolic nucleic acid sensors, and nucleotide-binding and oligomerization domain-like receptors; adaptors, kinases and other signaling molecules are required to elicit effective responses. Although this sensing is beneficial to the host, excessive activation and/or engagement by self molecules might induce autoimmune and other inflammatory disorders.
Journal of Experimental Medicine | 2004
Brian R. Lawson; Roberto Baccala; Jianxun Song; Michael Croft; Dwight H. Kono; Argyrios N. Theofilopoulos
A characteristic feature of systemic lupus erythematosus is the accumulation of activated/memory T and B cells. These G0/G1-arrested cells express high levels of cyclin-dependent kinase inhibitors such as p21, are resistant to proliferation and apoptosis, and produce large amounts of proinflammatory cytokines. Herein, we show that ablation of p21 in lupus-prone mice allows these cells to reenter the cell cycle and undergo apoptosis, leading to autoimmune disease reduction. Absence of p21 resulted in enhanced Fas/FasL-mediated activation-induced T cell death, increased activation of procaspases 8 and 3, and loss of mitochondrial transmembrane potential. Increased apoptosis was also associated with p53 up-regulation and a modest shift in the ratio of Bax/Bcl-2 toward the proapoptotic Bax. Proliferation and apoptosis of B cells were also increased in p21−/− lupus mice. Thus, modulation of the cell cycle pathway may be a novel approach to reduce apoptosis-resistant pathogenic lymphocytes and to ameliorate systemic autoimmunity.
Nature Reviews Rheumatology | 2010
Argyrios N. Theofilopoulos; Rosana Gonzalez-Quintial; Brian R. Lawson; Yi T. Koh; Michael E. Stern; Dwight H. Kono; Bruce Beutler; Roberto Baccala
Evidence strongly suggests that excessive or protracted signaling, or both, by cell-surface or intracellular innate immune receptors is central to the pathogenesis of most autoimmune and autoinflammatory rheumatic diseases. The initiation of aberrant innate and adaptive immune responses in autoimmune diseases can be triggered by microbes and, at times, by endogenous molecules—particularly nucleic acids and related immune complexes—under sterile conditions. By contrast, most autoinflammatory syndromes are generally dependent on germline or de novo gene mutations that cause or facilitate inflammasome assembly. The consequent production of proinflammatory cytokines, principally interferon-α/β and tumor necrosis factor in autoimmune diseases, and interleukin-1β in autoinflammatory diseases, leads to the creation of autoamplification feedback loops and chronicity of these syndromes. These findings have resulted in a critical reappraisal of pathogenetic mechanisms, and provide a basis for the development of novel diagnostic and therapeutic modalities for these diseases.